No Data
No Data
Jiankai Technology (688356): Short-term product sales are disrupted by multiple factors and the self-research pipeline is progressing in an orderly manner
The 2023 and 2024 quarterly results are in line with our expectations for 2023: revenue of $292 million, -28.26% year over year; net profit to mother of $116 million, or -38.05% year on year; deducting non-net profit 1.
Jiankai Technology (688356.SH) announced its 2023 annual results, with net profit of 116 million yuan, a decrease of 38.05%
Jiankai Technology (688356.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 2...
Jenkem Technology Co., Ltd.'s (SHSE:688356) CEO Xuan Zhao Is the Most Upbeat Insider, and Their Holdings Increased by 15% Last Week
Key Insights Significant insider control over Jenkem Technology implies vested interests in company growth A total of 4 investors have a majority stake in the company with 54% ownership Instituti
Innovative drug concepts continued to rise, and Jiankai Technology increased by more than 10%
The innovative drug concept continued to rise. Jiankai Technology rose more than 10%, Hyperui and Xinyuan rose more than 4%, and Zhijiang Biotech, Tonghua Jinma, and Guanhao Biotech followed suit.
Express News | Jiankai Technology: Application for registration of crosslinked sodium hyaluronate gel for injection was accepted
Jiankai Technology (688356.SH): Total cost of 7.686 million yuan to buy back 0.1713% of shares
Gelonghui, April 1, 丨 Jiankai Technology (688356.SH) announced that as of March 31, 2024, the company had repurchased 1038,1400 shares of the company's shares through centralized bidding transactions, accounting for 0.1713% of the company's total share capital. The highest price of the repurchase transaction was 75.05 yuan/share, the lowest price was 72.42 yuan/share, and the total amount of capital paid was RMB 7,686,044.60 (excluding transaction fees such as stamp duty and transaction fees).
No Data